Cello Health Dividends - CLL

Trade Now

Capital at risk

Stock Name	Stock Symbol	Market	Stock Type
Cello Health Plc	CLL	London	Ordinary Share

	Price Change	Price Change %	Stock Price	Last Trade
	0.00	0.0%	161.00	01:00:00

Open Price	Low Price	High Price	Close Price	Previous Close
			161.00	161.00

more quote information »

Industry Sector
MEDIA

Cello Health CLL Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
18/03/2020	Final	GBX	2.95	31/12/2018	31/12/2019	23/04/2020	24/04/2020	22/05/2020	4.1
18/09/2019	Interim	GBX	1.15	31/12/2018	31/12/2019	03/10/2019	04/10/2019	01/11/2019	0
21/03/2019	Final	GBX	2.75	31/12/2017	31/12/2018	25/04/2019	26/04/2019	24/05/2019	3.85
19/09/2018	Interim	GBX	1.1	31/12/2017	31/12/2018	04/10/2018	05/10/2018	02/11/2018	0
22/03/2018	Final	GBX	2.45	31/12/2016	31/12/2017	03/05/2018	04/05/2018	25/05/2018	3.5
20/09/2017	Interim	GBX	1.05	31/12/2016	31/12/2017	05/10/2017	06/10/2017	03/11/2017	0
22/03/2017	Final	GBX	2.4	31/12/2015	31/12/2016	04/05/2017	05/05/2017	26/05/2017	3.4
14/09/2016	Interim	GBX	1	31/12/2015	31/12/2016	06/10/2016	07/10/2016	04/11/2016	0
17/03/2016	Final	GBX	2.02	31/12/2014	31/12/2015	05/05/2016	06/05/2016	27/05/2016	2.86
16/09/2015	Interim	GBX	0.84	31/12/2014	31/12/2015	21/10/2015	22/10/2015	27/11/2015	0
19/03/2015	Final	GBX	1.8	31/12/2013	31/12/2014	30/04/2015	01/05/2015	29/05/2015	2.6
17/09/2014	Interim	GBX	0.8	31/12/2013	31/12/2014	01/10/2014	03/10/2014	07/11/2014	0
20/03/2014	Final	GBX	1.61	31/12/2012	31/12/2013	04/06/2014	06/06/2014	04/07/2014	2.25
18/09/2013	Interim	GBX	0.64	31/12/2012	31/12/2013	04/12/2013	06/12/2013	06/01/2014	0
13/03/2013	Final	GBX	1.42	31/12/2011	31/12/2012	29/05/2013	31/05/2013	05/07/2013	2
19/09/2012	Interim	GBX	0.58	31/12/2011	31/12/2012	07/12/2012	09/12/2012	04/01/2013	0
13/03/2012	Final	GBX	1.17	31/12/2010	31/12/2011	06/06/2012	08/06/2012	06/07/2012	1.72
13/09/2011	Interim	GBX	0.55	31/12/2010	31/12/2011	07/12/2011	09/12/2011	06/01/2012	0
15/03/2011	Final	GBX	0.9	31/12/2009	31/12/2010	08/06/2011	10/06/2011	08/07/2011	1.43
14/09/2010	Interim	GBX	0.525	31/12/2009	31/12/2010	06/10/2010	08/10/2010	03/11/2010	0
16/03/2010	Final	GBX	0.8	31/12/2008	31/12/2009	19/05/2010	21/05/2010	16/06/2010	1.3
15/09/2009	Interim	GBX	0.5	30/06/2008	30/06/2009	07/10/2009	09/10/2009	04/11/2009	0
17/03/2009	Final	GBX	0.75	31/12/2007	31/12/2008	20/05/2009	22/05/2009	17/06/2009	1.25
16/09/2008	Interim	GBX	0.5	30/06/2007	30/06/2008	08/10/2008	10/10/2008	05/11/2008	0
23/03/2008	Final	GBX	0.75	31/12/2006	31/12/2007	21/05/2008	23/05/2008	18/06/2008	1.2
20/03/2007	Final	GBX	0.6	31/12/2005	31/12/2006	23/05/2007	25/05/2007	15/06/2007	1
05/09/2006	Interim	GBX	0.4	30/12/2005	30/06/2006	20/09/2006	22/09/2006	13/10/2006	0

Top Dividend Posts

Date	Subject
05/6/2020 15:40	qs99: US market recovery and economic news today, may help CLL....let's see Read Full Thread Follow Reply
20/5/2020 08:39	davebowler: Cenkos- Navigating positively through disruptions Cello’s AGM statement should reassure that FY20 trading to date remains robust, underpinned by “solid” growth in net revenue in Q1/20. While Q2/20 saw certain early disruption, overall progress has been made to maintain revenues alongside effective cost controls, thus a creditable H1/20E result is expected. The 23% fall in the shares since February’s highs, appears to overly discount for the actual reality of this disruption.  Despite some disruption in Q2/20, the Cello Health division continues to perform:  Q1/20: Cello Health delivered “strong” overall net revenue and profit growth over Q1/20, benefitting from ISS’s acquisition in August 2019. On a LFL basis, excluding ISS, organic growth has been described as “good”, continuing recent momentum.  Q2/20: Commentary on trading post the COVID-19 outbreak suggests of continued progress, with new win rates being maintained, leading to a continuation of the typical six month visibility to bookings going into H2/20. This comes despite some disruption in activities requiring physical proximity (healthcare conventions, expert focus groups etc), which are being digitally delivered or have been put on hold.  Some COVID-19 benefits: New projects have arisen as result of the pandemic, with Cello Connect, the digital and creative marketing capability transferred from Signal, delivering COVID-19 related public health campaigns, while newly acquired ISS is also benefitting from new US regulatory drug approvals and FDA fillings.  Signal expected to be more impacted, but it’s far less material this year: Cello Signal generated only 16% of net revenue in Q1/20 following Connect’s transfer at the start of the year. Over Q2/20 and beyond, trading is unsurprisingly expected to be challenged by COVID-19, given certain clients are engaged in troubled sectors (eg travel, leisure), thus some delays and cancellations are expected. As such, cost control measures have, and continue to be undertaken, where necessary.  Balance sheet remains strong: Today’s update confirms Cello maintains a “solid” net cash position. This comes despite a seasonal working capital outflow in Q1/20 and is inclusive of a £0.7m payment for the final earn-out payment on Defined Health and FY19A’s £1.1m final dividend. The implies positive cash generation to date this year.  Valuation: Prior to the COVID-19 outbreak, Cello traded at a forward P/E of 16.0x in late February, a multiple we feel is merited. If Cello were to deliver a FY20E result largely consistent with FY19A, a price today of 151p p/s (+32% upside) would be fair. Read Full Thread Follow Reply
07/4/2020 12:37	coopstock: Cutting the dividend just one week after announcing the award of all those new share options for senior directors. All in this together - I don't think so. Pretty poor. Read Full Thread Follow Reply
07/4/2020 08:41	poikka: I suppose that the idea of cutting the divi so soon after announcing it, is designed to demonstrate solidarity with those taking a pay cut. The saving, even if it is (hopefully) temporary, would be some £2m. 1. It sounds like a noble gesture - 'we're all in this together'. 2. As the situation hasn't really changed, nor has the outlook, since the results, it looks odd. They could have just not increased the divi at the results. 3. Companies cutting divis without very good reason are removing cash from the economy when it's really going to be needed, and there are many people who rely on divis for their sole, or nearly sole, income. A wrong decision, therefore, in my book. Read Full Thread Follow Reply
06/4/2020 18:08	poikka: (Alliance News) - Access Intelligence PLC on Monday reported a widened loss for financial 2019 on increased expenses but assured that the first quarter of financial 2020 has been encouraging. The stock was trading 3.0% higher at 51.00 pence each on Monday afternoon in London. For the year to the end of November, the PR, communications and marketing software firm recorded revenue of GBP13.4 million, a 51% rise from GBP8.9 million reported the year prior with recurring revenue accounting for 97% of revenue realised. However, pretax loss widened to GBP2.9 million from GBP1.7 million. Gross margin was 75% from 70% the year prior. Recurring administrative expenses increased to GBP9.2 million from GBP6.2 million and the company recorded non-recurring administrative expenses of GBP1.8 million. In October, GBP3.3 million was raised through the placing of 6.3 million shares at 52p each. Access Intelligence did not propose a dividend payout, unchanged from the year prior. Looking ahead, the company said it has seen increased demand for Vuelio stakeholder monitoring, media management and Pulsar's online audience analysis amid the Covid-19 outbreak. It added that it has implemented measures to reduce financial risk and has responded fast and proactively to secure business and open new opportunities during the period of disruption. "2019 was another year of strong growth for Access Intelligence. Our commitment to growth was evidenced by the acquisition of Pulsar and further product enhancements to the Vuelio and ResponseSource platforms, said Non-Executive Chair Christopher Satterthwaite. Vuelio provides monitoring, insight, engagement and evaluation tools for social media, while ResponseSource is a media database provider. Access Intelligence bought social media analytics software business Pulsar from Cello Health in October. "Pulsar is a particularly exciting addition because it strengthens our technology, data and research capabilities while opening US and global opportunities. It adds further breadth to the Access Intelligence portfolio and customer base providing resilience as we navigate the immediate uncertainty bought by Covid-19," he added. Read Full Thread Follow Reply
18/3/2020 08:18	poikka: Not much at all, so far. In the present climate, a 7.2% divi rise is welcome. Read Full Thread Follow Reply
03/3/2020 12:18	zipstuck: As the major drug companies are being squeezed on supply chains you have to wonder how this might affect CLL Read Full Thread Follow Reply
18/7/2019 19:20	qs99: nice uptick today. A guarded upgrade IMO, yet market hasn't really digested it....more to come, maybe increase in divi? DYOR Read Full Thread Follow Reply
18/7/2019 10:26	qs99: if that is an average of the peer group, how long before someone takes "a look" at CLL? or management get bored with the share price and do something about it?! DYOR Read Full Thread Follow Reply
21/1/2019 09:20	zipstuck: Reasonable divi with some growth to come Read Full Thread Follow Reply

Advertise Here

Your Recent History

LSE

CLL

Cello Heal..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20220810 19:45:55